ArticleHead and neck pathology2026
Immunohistochemical Predictors in Head and Neck Mucosal Melanoma.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal melanoma is a rare disease with a poor prognosis, and its clinical signs and symptoms are nonspecific. This study aims to identify histopathological features and immunohistochemical markers of head and neck mucosal melanoma that characterize the tumor immunophenotype and are associated with patient survival.
methodsThe study analysed head and neck mucosal melanoma diagnosed at Helsinki University hospital between January 1, 2011, and June 8, 2023. Samples were obtained from the Helsinki Biobank in Finland. New slides were prepared and stained for hematoxylin and eosin (H&E), CD3, CD4, CD8, Granzyme B (GrzB), CD68, CD117, p16INK4a, p53, SOX10 and PRAME.
resultsThe study included 23 patients, 10 men and 13 women, aged 60-92 years (mean 75 years). The tumors were predominantly sinonasal. Ulceration was present in 15 cases, also 15 cases were amelanotic. Immunohistochemical staining SOX10 was positive in all tumors. PRAME was strongly positive in majority (20 cases, 87%). Strong p16 positivity was observed in 13 cases (57%), with a longer median survival compared to cases with weakened p16 expression (32.8 vs 13.8 months, p = 0.176). The median survival was also longer in the cases with high score of tumor infiltrating CD3-, CD8- and CD68-positive immune cells, though not statistically significant.
conclusionsImmunohistochemical markers routinely applied in cutaneous melanoma (SOX-10 and PRAME) are also expressed in head and neck mucosal melanoma. Tumour-infiltrating immune cells showed trend toward better survival, as has been previously found out in cutaneous melanoma. Strong p16 positivity may be an independent predictor of favorable prognosis in head and neck mucosal melanoma, irrespective of disease stage. Larger multicenter studies are warranted to validate these findings in this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.